NICE TA Adherence Check List KEY NICE TA PAS Not Terminated Indication Technology Appraisal carried out by the National Institute of Clinical Excellence - It is the process by which new and existing drugs or procedures are evaluated. Following this evaluation the drug or procedure is approved or not approved for use in the NHS Patient Access Scheme - discount scheme agreed between the manufacturer of the drug and the Department of Health which enables patient access to high cost drugs If clinically appropriate NICE has recommended the drug can be use for the indication stated. NICE has reviewed the drug and has recommended the drug CANNOT be used for the indication stated No evidence was received by NICE from the manufacturer of the drug so NICE were unable to proceed with the appraisal Reason to prescribe the specified drug Colour Key Implemented with 90 days of TA release Not implemented within the 90 days of TA release NICE TA Indication Drug Approval Release Date Available on Local Formulary TA274 Diabetic macular oedema Ranibizumab 27/02/13 TA275 Stroke & Systemic embolism Apixaban 27/02/13 TA267 Heart Failure II - IV Ivabradine 28/11/12 TA260 Chronic migraine Botulinum toxin A 27/11/12 TA265 Bone Metastases for solid tumours Denosumab 24/10/12 TA264 Acute ischaemic stoke Alteplase 26/09/12 TA261 deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism Rivaroxaban 25/07/12 TA256 Stroke prevention in AF Rivaroxaban 23/05/12 TA249 Stroke prevention in AF Dabigatran etexilate 15/03/12 TA247 Rheumatoid arthritis Tocilizumab with PAS 22/02/12 TA248 Type 2 diabetes Exenatide LAR 22/02/12 TA244 COPD Roflumilast 25/01/12 TA245 Prevention of VT after total Hip or Knee replacement in Adults Apixaban 25/01/12 TA236 ACS Ticagrelor 26/10/11 TA233 Ankylosing spondylitis Golimumab with PAS 24/08/11 TA229 Macular oedema associated with retinal vein occlusion Dexamethasone implant (Ozurdex) 27/07/11 TA232 Partial onset seizures Retigabine 27/07/11 TA225 Rheumatoid arthritis (2nd line ) Golimumab with PAS 22/06/11 TA223 Intermiittent claudication associated with peripheral vasular disease Naftidrofuryl oxalate 25/05/11 TA220 Psoriatic arthritis Golimumab with PAS 27/04/11 Donepezil 23/03/11 Galantamine 23/03/11 TA217 Alzheimer's disease Memantine 23/03/11 Rivastigmine 23/03/11 Rivastigmine (patch) 23/03/11 Alendronate 26/01/11 TA160 Osteoporosis Primary prevention Etidronate 26/01/11 Risedronate 26/01/11 Strontium ranelate 26/01/11 Teriparatide 26/01/11 Alendronate 26/01/11 TA161 Osteoporosis Secondary Prevention Etidronate 26/01/11 Risedronate 26/01/11 Strontium ranelate 26/01/11 Raloxifene 26/01/11 TA213 Schizophrenia (15-17yo) Aripiprazole (oral) 26/01/11 TA210 Occlusive vascular events Clopidogrel 15/12/10 Dipyridamole (MR) 15/12/10 TA211 Refractory constipation in women Prucalopride 15/12/10 TA203 Type 2 diabetes Liraglutide 27/10/10 TA204 Post-menopausal osteoporosis Denosumab 27/10/10 Abatacept 25/08/10 Notes
Adalimumab 25/08/10 TA195 RA (after failure of TNF) Etanercept 25/08/10 Infliximab 25/08/10 Rituximab 25/08/10 TA197 AF Dronedarone 25/08/10 Adalimumab 25/08/10 TA199 Psoriatic arthritis Etanercept 25/08/10 Infliximab 25/08/10 TA188 Growth failure in children Somatropin 26/05/10 TA187 Crohn's disease Adalimumab 19/05/10 Infliximab 19/05/10 TA186 Rheumatoid arthritis Certolizumab pegol with PAS 24/02/10 TA182 ACS Prasugrel 28/10/09 TA180 Psoriasis Ustekinumab with PAS 23/09/09 TA177 Chronic hand eczema Alitretinoin 26/08/09 TA170 VTE prophylaxis (post hip or knee replacement) Rivaroxaban 22/04/09 TA168 Treatment of influenza Oseltamivir 25/02/09 Zanamivir 25/02/09 TA164 Hyperuricaemia Febuxostat 17/12/08 TA163 UC (acute exacerbations) Infliximab 17/12/08 This guidance relates to the use of infliximab within it marketing authorisation. Therefore in children between the ages of 6 to 17 who meet the clinical criteria their treatment would funded via Commissioning Board TA157 VTE prophylaxis (post hip or knee replacement) Dabigatran etexilate 24/09/08 TA158 Prevention of influenza Oseltamivir 24/09/08 Zanamivir 24/09/08 TA155 AMD Ranibizumab 27/08/08 TA146 Psoriasis Adalimumab 25/06/08 TA142 TA143 Ca treatment-induced anaemia Ankylosing spondylitis Darbopoetin Adalimumab Epoetin alfa, beta & delta Etanercept TA134 Psoriasis Infliximab 23/01/08 TA132 Hypercholesterolaemia Ezetimibe 28/11/07 Adalimumab 24/10/07 TA130 RA (first TNF) Etanercept 24/10/07 Infliximab 24/10/07 TA123 Smoking Cessation Varenicline 25/07/07 Anastrozole 22/11/06 TA112 Breast Ca Exemestane 22/11/06 Letrozole 22/11/06 TA103 Psoriasis Etanercept 26/07/06 TA82 Eczema Pimecrolimus 01/08/04 Tacrolimus 01/08/04 TA77 Insomnia Zaleplon 01/04/04 TA68 PDT of AMD Verteprofin 01/09/03 TA64 Growth hormone deficiency in adults Somatropin 01/08/03 TA53 Type 1&2 diabetes Insulin glargine 01/12/02 Alteplase 01/10/02 TA52 Acute MI Reteplase 01/10/02 Streptokinase 01/10/02 Tenecteplase 01/10/02 TA20 MND Riluzole 01/01/01 TA268 Metastatic melanoma Ipilimumab 12/12/12 TA269 Locally Adv. Or metastatic BRAF V600 mutation-positive unresectable metastatic Verumafenib 12/12/12 TA266 Cystic Fibrosis Mannitol 28/11/12 TA258 NSCLC with EGFR activating mutations Erlotinib with PAS 27/06/12 TA259 Metastatic Castration resistant Prostate Ca Abiraterone (Zytiga) 27/06/12 TA252 Genotype 1 chronic Hepatitis C Telaprevir 25/04/12 TA253 Genotype 1 chronic Hepatitis C Bocepravir 25/04/12 TA254 highly active relapsing remitting multiple sclerosis (In Adults) Fingolimod with PAS 25/04/12
TA246 Hypersensitivity to bee & wasp venom Pharmalgen 22/02/12 TA243 1st line Treatment of Follicular Lymphoma stages III - IV Rituximab 25/01/12 Cyclophosphamide 25/01/12 TA241 CML dasatinib, nilotinib, imatinib (intolerant, resistant) Nilotinib 13/01/12 TA238 Juvenile Idiopathic systemic arthritis Tocilizumab with PAS 14/12/11 TA235 Osteosarcoma Mifamurtide 26/10/11 TA228 Mulitple myeloma (1st line) Thalidomide 27/07/11 Bortezomib 27/07/11 TA230 STEMI undergoing primary PCI Bivalirudin 27/07/11 TA226 Follicular NHL (maintenance) Rituximab 22/06/11 TA221 Idiopathic thrombocytopenia purpura Romiplostim with PAS 27/04/11 TA218 Myelodysplastic syndrome Azacitidine with PAS 23/03/11 TA215 Metastatic renal cell Ca (1st line) Pazopanib with PAS 23/02/11 TA216 CLL (1st line) Bendamustine 23/02/11 TA86 & TA209 Unresectable/metastatic GIST Imatinib 24/11/10 TA191 Advanced gastric Ca Capecitabine 28/07/10 TA192 Locally-advanced or metastatic NSCLC (1st line) Gefitinib with PAS 28/07/10 TA193 CLL (relapsed or refractory) Rituximab in combination with fludarabine & cyclophosphamide 28/07/10 TA190 NSCLC (maintenance) Pemetrexed 23/06/10 TA185 Advanced soft tissue sarcoma Trabectedin with PAS 24/02/10 TA184 Relapsed SCLC Topotecan (oral) 25/11/09 TA183 Cervical Ca Cisplatin (in combination) 28/10/09 Topotecan 28/10/09 TA179 GIST Sunitinib with PAS 23/09/09 TA181 NSCLC (1st line) Pemetrexed 23/09/09 TA176 Colorectal Ca (first line) Fluorouracil with PAS 26/08/09 TA176 Metastatic colorectal Ca (1st line) Cetuximab with PAS 26/08/09 TA173 Hepatitis B Tenofovir disoproxil 22/07/09 Cyclophosphamide 22/07/09 TA174 CLL Fludarabine phosphate 22/07/09 Rituximab 22/07/09 TA171 Mulitple myeloma Lenalidomide with PAS 18/06/09 TA169 Renal cell Ca (1st line) Sunitinib 25/03/09 TA162 NSCLC - treatment Erlotinib with PAS 26/11/08 TA153 Hepatitis B Entecavir 27/08/08 TA151 Type 1 diabetes CSII (adults & Children over 12 years & over) 23/07/08 TA145 Head & neck Ca (locally advanced) Cetuximab 25/06/08 TA137 Follicular non-hodgkin's lymphoma Rituximab 27/02/08 TA135 Mesothelioma Pemetrexed 23/01/08 TA133 Asthma - over 12yo & adults Omalizumab 28/11/07 TA129 Relapsed Multiple myeloma Bortezomib with PAS 24/10/07 TA127 Multiple sclerosis Natalizumab 22/08/07 TA121 Glioma Carmustine (implant) 27/06/07 Temozolomide 27/06/07 TA116 Metastatic breast Ca Gemcitabine 24/01/07 Paclitaxel 24/01/07 TA117 Secondary hyperparathyroidism Cinacalcet 24/01/07 Doxorubicin hydrochloride 21/09/06 TA109 Early Breast Ca Cyclophosphamide 21/09/06 Docetaxel 21/09/06 TA106 Hepatitis C (mild) Peginterferon alfa 26/08/06 Ribavirin 26/08/06 TA107 Early breast Ca Trastuzumab 23/08/06 TA101 Prostate Ca Docetaxel 28/06/06 Capecitabine 26/04/06 TA100 Colon Ca Fluorouracil 26/04/06 Oxaliplatin 26/04/06 TA99 Renal transplantation (adults) Basiliximab 26/04/06 TA96 Hepatitis B Adefovir dipivoxil 22/02/06 Peginterferon alfa 22/02/06 Doxorubicin hydrochloride (peg.lipsomal) 01/05/05 Topotecan 01/05/05
TA91 Ovarian Ca (advanced) Carboplatin 01/05/05 Cisplatin 01/05/05 Paclitaxel 01/05/05 TA85 Renal transplantation (adolescents & children) Basiliximab 22/09/04 Interferon alfa 01/01/04 TA75 Hepatitis C (moderate-severe) Peginterferon alfa 01/01/04 Ribavirin 01/01/04 TA70 CML Imatinib 01/10/03 Cyclophosphamide 01/09/03 TA65 Non-Hodgkin's lymphoma Rituximab 01/09/03 Doxorubicin hydrochloride 01/09/03 TA61 Metastatic colorectal Ca Capecitabine 01/05/03 Tegafur with uracil 01/05/03 TA55 Ovarian Ca Paclitaxel 01/01/03 TA35 Juvenile arthritis Etanercept 01/03/02 TA25 Pancreatic Ca Gemcitabine 01/05/01 TA23 Brain cancer Temozolomide 01/04/01 Buprenorphine 01/01/07 TA114 Managing Opiod Dependancy Methadone 01/01/07 Naltrexone 01/01/07 NICE Indication Drug Approval Release Date Available on Local Formulary TA271 Diabetic macular oedema Fluocinolone implant Not approved 23/01/13 No TA272 TCCU Vinflunine Not approved 23/01/13 No TA273 Benign Prostatic Hyperplasia Tadalafil Terminated 23/01/13 No TA270 AML Decitabine Not approved 12/12/12 No TA263 Adv/Metastatic breast Ca 1st line Bevacizumab Not approved 22/08/12 No TA257 HER2 +ve metastatic breast Ca Lapatinib Not approved 27/06/12 No Trastuzumab Not approved 27/06/12 No TA262 Moderate-severe UC (2nd line) Adalimumab Not approved 27/06/12 No TA255 Metastatic prostate Ca Cabazitaxel Not approved 11/05/12 No TA251 CML 1st line Dasatinib Not approved 25/04/12 No TA250 Locally advanced or metastatic breast cancer Eribulin Not approved 03/04/12 No TA242 Cetuximab Not approved 25/01/12 No Metastatic colorectal Ca (2nd line) Bevacizumab Not approved 25/01/12 No TA240 Colorectal Cancer (Metastatic) Panitumumab Not approved 25/01/12 No TA241 CML dasatinib, nilotinib, imatinib (intolerant, resistant) Dasatinib Not approved 13/01/12 No Imatinib Not approved 13/01/12 No TA239 Breast Ca Fulvestrant Not approved 14/12/11 No TA240 Metastatic colorectal Ca (2nd line) Panitumumab Terminated 14/12/11 No TA206 Indolent NHL Bendamustine Not approved 27/10/11 No TA234 RA (first TNF) Abatacept Not approved 24/08/11 No TA231 Depression Agomelatine Not approved 27/07/11 No TA227 NSCLC - maintenance Erlotinib Not approved 29/06/11 No TA224 RA (methotrexate-naïve) Golimumab Terminated 22/06/11 No TA223 Cilostazol Not approved 25/05/11 No Intermiittent claudication associated with peripheral vasular disease Inositol nicotinate Not approved 25/05/11 No Naftidrofyryl Oxalate Not approved 26/05/11 No Pentoxifylline Not approved 25/05/11 No TA222 Relapsed ovarian Ca Trabectedin Not approved 27/04/11 No TA219 Advanced RCC (2nd line) Everolimus Not approved 19/04/11 No TA214 Metastatic breast Ca Bevacizumab Not approved 23/02/11 No TA160 Primary prevention of osteoporosis Raloxifene Not approved 26/01/11 No TA212 Metastatic colorectal Ca Bevacizumab Not approved 15/12/10 No TA208 HER2 +ve metastatic gastric Ca Trastuzumab Not approved 24/11/10 No TA201 Asthma - 6-11yo Omalizumab Not approved 27/10/10 No TA206 Non-Hodgkin's lymphoma Fesoterodine Not approved 27/10/10 No TA202 CLL Ofatumumab Not approved 27/10/10 No TA205 Idiopathic thrombocytopenia purpura Eltrombopag Not approved 27/10/10 No TA207 Mantle cell lymphoma Temsirolimus Terminated 27/10/10 No TA196 GIST (adjuvant) Imatinib Not approved 25/08/10 No TA189 Hepatocellular Ca Sorafenib Not approved 26/05/10 No Notes
Bevacizumab Not approved 29/08/09 No TA178 Renal cell Ca Sorafenib Not approved 29/08/09 No Temsirolimus Not approved 29/08/09 No Renal cell Ca (2nd line) Sunitinib Not approved 29/08/09 No TA172 Head & neck Ca (recurrent or metastatic) Cetuximab Not approved 24/06/09 No TA168 Treatment of influenza Amantadine Not approved 25/02/09 No TA158 Prevention of influenza Amantadine Not approved 24/09/08 No TA154 Hepatitis B Telbivudine Not approved 27/08/08 No TA155 AMD Pegaptanib sodium Not approved 27/08/08 No TA148 NSCLC Bevacizumab Not approved 25/06/08 No TA149 Glioblastoma multiforme Carmustine (implant) Not approved 25/06/08 No TA143 Ankylosing spondylitis Infliximab Not approved No TA140 UC (sub-acute manifestations) Infliximab Not approved 23/04/08 No TA124 NSCLC (2nd line) Pemetrexed Not approved 22/08/07 No TA119 CLL Fludarabine phosphate Not approved 28/02/07 No Bevacizumab Not approved 24/01/07 No TA118 metastatic colorectal Ca Fluorouracil Not approved 24/01/07 No Cetuximab Not approved 24/01/07 No TA108 Early breast Ca Paclitaxel Not approved 27/09/06 No TA84 Sepsis Drotrecogin alfa Withdrawn 22/09/04 No